Catalyst Pharmaceuticals To Present Firdapse Phase 3 Trial Results At The 61st Annual Meeting Of The American Association Of Neuromuscular And Electrodiagnostic Medicine

Catalyst Pharmaceutical Partners, Inc.

(Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that safety and efficacy results from its Firdapse™ Phase 3 trial will be presented as part of an Industry Forum at the 61st Annual Meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) being held at the Savannah, Georgia International Trade and Convention Center, Oct. 29-Nov. 1. The Catalyst-sponsored forum will occur on Friday, Oct, 31 at 12:00 pm EDT and include presentations on the diagnosis and treatment of LEMS and Congenital Myasthenic Syndrome (CMS) by several Firdapse Phase 3 clinical study investigators and the Firdapse Expanded Access Program (EAP) by Catalyst's chief medical officer. Catalyst will also be exhibiting at booth #515 during the AANEM. The presentation materials will be posted at www.catalystpharma.com in the Investors section under Events & Presentations. October 31st Agenda: "New Advances in the Diagnosis and Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)" Clinical Features and Pathophysiology of Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndrome (CMS) Perry Shieh, MD, PhD Associate Professor Director, Neuromuscular Program UCLA Medical Center Electrodiagnosis and Management of LEMS Yuen So, MD, PhD Professor of Neurology Chief, Neurology Clinic Stanford University Medical Center Initial Firdapse™ Pivotal Phase 3 Study Safety Results Mazen Dimachkie, MD Professor of Neurology University of Kansas Medical Center Initial Firdapse™Pivotal Phase 3 Study Efficacy Results Shin J. Oh, MD Distinguished Professor Emeritus University of Alabama at Birmingham Medical Center Serving the LEMS Patient - Firdapse™ Expanded Access Program Charles Gorodetzky, MD, PhD Chief Medical Officer Catalyst Pharmaceuticals Further information can be found at: http://catalystpharma.com/pdf/CPP14006_Invite_RD27R2_WEB.pdf